Akeso, Inc. (HKG: 9926)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
54.90
+6.70 (13.90%)
Sep 9, 2024, 2:23 PM HKT
57.31%
Market Cap 41.73B
Revenue (ttm) 2.01B
Net Income (ttm) -790.12M
Shares Out 865.86M
EPS (ttm) -0.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 27,817,431
Open 55.00
Previous Close 48.20
Day's Range 50.50 - 55.00
52-Week Range 26.45 - 60.00
Beta 0.52
Analysts n/a
Price Target n/a
Earnings Date Nov 28, 2024

About Akeso

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovari... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 2,778
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9926
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.